Harvard Bioscience Stock Price and Value Analysis

Harvard Bioscience (NasdaqGM:HBIO) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Harvard Bioscience to reach your target.

Target type

HBIO Free Cash Flow Trend

Free Cash Flow trendline for HBIO
Free Cash Flow trendline for Harvard Bioscience

Hmm, we can't give any reliable projection for Harvard Bioscience's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
  • This company is solid.
  • This stock looks overpriced.
  • This company is not making money.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the HBIO Numbers

HBIO Price
(Harvard Bioscience stock price per share)
$9.08
[?] PE Ratio versus Sector 3121% higher than other Technology stocks
[?] PE Ratio versus Industry 2608% higher than other Scientific & Technical Instruments stocks
[?] Cash Yield 10.06%
[?] Free Cash Flow Jitter 77%

Insider Activity Summary

No open-market insider buys or sells are recorded in the six months to 2026-11-17.

The six months before that had 5 buys and 0 sales.

Recent Insider Activity

Open-market buys and sells reported by Harvard Bioscience's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2026-03-17 DENELSKY STEPHEN J Buy 10,000 $4.87
2026-03-17 Snider William Buy 8,475 $4.85
2026-03-16 Frost Mark T (Chief Financial Officer) Buy 5,000 $5.00
2026-03-16 Snider William Buy 12,525 $4.99
2026-03-16 Duke John D (Chief Executive Officer) Buy 5,000 $5.01

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 66,461 shares shorted. With 3,693,814 shares available for purchase and an average trading volume over the past 10 trading days of 39,870, it would take at least 1.7 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

Price Versus Our Estimated Value

Only 15 of the 17 fiscal years under Harvard Bioscience's current filer show positive free cash flow.

The latest three years average $5.8 million in free cash flow against $11.8 million for the earliest three, which is a sharp decline.

Free cash flow is volatile from year to year, with a variability measure of 77%.

We do not estimate a fair value for Harvard Bioscience while its free cash flow growth is not positive, so there is no value comparison here.

No dividend yield is recorded for Harvard Bioscience in our data.

Before you act on any of this, read what a margin of safety means and check the company's own filings.

Compared With Its Sector and Industry

Its trailing P/E ratio is 3121% above the average for stocks in the Technology sector.

Its trailing P/E ratio is 2608% above the average for stocks in the Scientific & Technical Instruments industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1123494.

Each figure on this page comes from that filer.

Risks to This Analysis

  • Free cash flow was negative in 2 of the 17 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • We have no value estimate for this stock, so no price comparison is made.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in HBIO

Does Harvard Bioscience have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: HBIO

This example shows how we apply the Trendshare checklist to HBIO: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 9.08
    • Market cap: $42M
    • EPS: -2.59
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: 9.9%
    • Date checked: Nov 17, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.